Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM)

NCT03914768 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT03914768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03914768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM)
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2029
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma or glioblastoma